About
Small molecules for neurology
Areas of Focus
Categories
Small Molecule PharmaceuticalNJ, NY, PA
Clinical Trials (42)
View allTotal Trials
42
As Lead Sponsor
38
As Collaborator
4
Total Enrollment
10,746
By Phase
PHASE1: 11PHASE3: 18PHASE2: 9PHASE4: 1PHASE1/PHASE2: 3
By Status
COMPLETED: 22RECRUITING: 16TERMINATED: 3ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline42 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT06786286Lead Sponsor
A Mass Balance Study Following Subcutaneous Administration of [14C]-ITI-1284 to Healthy Male Subjects
PHASE1Completed
8 participants
Started: Jan 28, 2025 · Completed: Mar 26, 2025
NCT06706674Lead Sponsor
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients
PHASE3Recruiting
174 participants
Started: Dec 6, 2024 · Completed: Apr 30, 2027
NCT06690398Lead Sponsor
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients
PHASE3Recruiting
174 participants
Started: Nov 22, 2024 · Completed: Apr 30, 2027
NCT06701903Lead Sponsor
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
PHASE2Recruiting
570 participants
Started: Nov 21, 2024 · Completed: Jun 30, 2027
NCT06651567Lead Sponsor
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
PHASE2Recruiting
320 participants
Started: Oct 22, 2024 · Completed: Nov 30, 2027
Locations (1)
Headquarters
New York, NY, United States
Map
Loading map...